Human RCT
Mensch
As an adjunct to insulin therapy, lowers postprandial blood-glucose spikes and modestly reduces HbA1c.
What does NOT follow: Approved only as an adjunct to insulin; not as monotherapy. Hypoglycemia risk in combination with insulin.
Peptide entry · Metabolic
Pramlintid
Pramlintide · Symlin · Pramlintide acetate
Highest evidence
Human RCT
Studies recorded
0
Legal status · US
PrescriptionScientific context only. Not medical advice, not a recommendation to use.
At a glance
Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying.
Researched for
Type 1 diabetes (adjunct)Type 2 diabetes (adjunct)Postprandial glucoseSatiety
Official status
US: Prescription
FDA-approved (2005, Symlin) as an adjunct to mealtime insulin therapy.
At a glance
Overview
What is it?
Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying.
How is it meant to work? →
Pramlintide mimics the beta-cell hormone amylin, which is co-secreted with insulin. It slows gastric emptying, suppresses postprandial glucagon release and promotes satiety — thereby blunting post-meal blood-glucose spikes.
What do studies show? →
Human RCTAs an adjunct to insulin therapy, lowers postprandial blood-glucose spikes and modestly reduces HbA1c.
What do users report?
No documented community reports.
01
Mechanism of action
Pramlintide mimics the beta-cell hormone amylin, which is co-secreted with insulin. It slows gastric emptying, suppresses postprandial glucagon release and promotes satiety — thereby blunting post-meal blood-glucose spikes.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
03
What the studies show
Human trial
Mensch
Associated with modest weight loss (meta-analysis: around 2.3 kg).
What does NOT follow: Effect smaller than with GLP-1 agents; studied in obesity trials in non-diabetics but not approved for that.
04
Where studies disagree
Open question
Is pramlintide still clinically relevant given the GLP-1 agents?
POSITION A
As the only approved amylin analog, it addresses a distinct mechanism (glucagon, gastric emptying, satiety) complementary to insulin.
POSITION B
GLP-1 and dual/triple agonists usually achieve stronger glucose and weight effects with a simpler regimen; the extra mealtime injection limits uptake.
CURRENT STATE · A niche as an insulin adjunct; the amylin principle is, however, seeing a renaissance via newer analogs (e.g. cagrilintide).
05
Pharmacokinetics
No robust pharmacokinetic human data available. A model curve is not invented.
06d
Safer use & risks
Risk notes for harm reduction — descriptive, not a usage or dosing guide.
This substance is approved (in at least one country) — use belongs in medical hands, within the approved indication and a physician-set dose.
Online numbers are not a benchmark
Amounts from TikTok, YouTube and forums are mostly imitation rather than data — and are often wrongly derived from animal studies (µg/kg). Not a reliable benchmark for humans.
Sterility & infection risk
Injection solutions prepared or stored non-sterile carry an infection and abscess risk. Contamination is common with grey-market product.
Unknown product quality
Research-/grey-market product is not quality-tested: identity, purity and actual content are often unknown, and counterfeits occur.
Mind interactions
Combinations with medications or pre-existing conditions can carry risks (see the Interactions section). Clarify with a doctor beforehand.
Warning signs — seek medical help
With persistent pain, redness/swelling at the injection site, fever, shortness of breath, racing heart, chest pain or allergic reactions, seek medical help immediately.
A doctor, not a forum
Concrete questions about use and amount belong in a conversation with a doctor — not in a comment thread.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Human RCT
Nausea
Most common effect, usually early and transient.
sehr häufig
Human RCT
Severe hypoglycemia (in combination with insulin)
Carries an FDA boxed warning for hypoglycemia risk in combination with insulin — documented safety information, not a usage instruction.
Warnhinweis (Boxed Warning)
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
11
Legal status by country
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
- 1Enter the vial's substance amount (printed on the label).
- 2Enter how much solvent you add.
- 3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.
15
Sources & method
Last reviewed
2026-06-11
Get new studies on Pramlintid
Science only, no sales. Unsubscribe anytime.
We store your email only for the newsletter. Unsubscribe anytime. Privacy